retatrutide side effects phase 2 trial VisualAbstract: reduces body weight by 17.5% in patients with obesity The FDA has issued warning

The LEADER trial demonstrated a significant reduction in the rate of cardiovascular death, nonfatal MI, or nonfatal stroke in patients with type II diabetes treated with liraglutide

Released as a white paper entitled From Weight Loss to Lasting Value: Structured Exercise and the Economics of GLP-1 Therapy, the research compares impacts of GLP-1 therapy as a standalone obesity treatment with GLP-1 therapy combined with exercise in five countries

Zepbound vs

That can slow how the dose is used and is a known issue, particularly in women and larger patients where there is more tissue to pass through

These medicines are transforming obesity treatment and can achieve important weight loss